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Background: Overexpression of vascular endothelial growth factor 
receptor (VEGF-R) in NSCLC-tumors is linked to poor prognosis and 
short-term overall survival (OS). PTK/ZK is a novel, oral, anti-angio-
genic compound that inhibits all known VEGF receptors (VEGF-R1-3). 
Methods: A prospective, single-arm, multi-center, proof-of-principle 
phase-II study was conducted to investigate efﬁcacy and safety of PTK/
ZK in pretreated patients (pts) with stage IIIB/IV NSCLC. Only one 
platinum-based chemotherapy regimen was permitted as prior ﬁrst-line 
treatment. 55 pts were planned for each treatment group and partici-
pants received either a ﬁxed dose of 1250 mg PTK/ZK once daily (qd) 
or twice daily (500 mg a.m. + 750 mg p.m.) (bid) for continuous treat-
ment until disease progression or the incidence of unacceptable toxici-
ties. Response evaluation was based on RECIST. A disease stabiliza-
tion (SD) of at least 12 weeks based on CT/MRI-imaging was deﬁned 
as clinically relevant drug activity. Additional biomarker evaluation 
included DCE-MRI and serum proteomics.
Results: Enrolment is completed with 54 pts starting qd treatment and 
58 pts starting bid treatment. Most frequent adverse events in both 
cohorts were nausea (44%), vomiting (40%), and dizziness (34%). 
Three deaths possibly-related to treatment were observed; 2 incidences 
of pulmonary hemorrhage and 1 pulmonary embolism. Response rates 
measured by RECIST for the qd cohort (n=54) include 1 patient with 
a conﬁrmed partial response (cPR) (2%), 32 (59%) with stable disease 
(SD) at week 4 and hereof 18 patients with SD (33%) for at least 12 
weeks and 21 pts (39%) with progressive disease (PD). The bid cohort 
included (n=57) 4 patients with cPR (7%), 18 pts (32%) with SD (>12 
weeks), 19 pts (33%) not yet evaluated, and 16 pts (28%) with PD. 
Progression free survival (PFS)/OS were 2.4/7.0 months (mo) for the 
qd vs. 3.7/6.8 mo for the bid cohort.
Conclusions: These results suggest that both qd and bid second-line 
treatment with single-agent PTK/ZK is generally safe and well toler-
ated. In this unfavorable patient population a considerably high rate 
of disease control could be achieved. Four patients with PR out of 38 
evaluated pts in the bid cohort might indicate additional beneﬁt of bid 
dosing. Final data of the primary endpoint (efﬁcacy) for both cohorts 
will be presented at the meeting.
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Background: Vandetanib (ZACTIMA™; ZD6474) is a once-daily, oral 
anticancer drug that selectively inhibits vascular endothelial growth 
factor receptor (VEGFR), epidermal growth factor receptor (EGFR) 
and RET (REarranged during Transfection) receptor tyrosine kinase 
activity. The activity of vandetanib alone, vandetanib in combination 
with carboplatin/paclitaxel (CP), or CP + placebo was assessed in 
patients with previously untreated locally advanced or metastatic (IIIB-
IV) NSCLC.
Methods: This two-part, multicenter Phase II study comprised an 
open-label, safety run-in phase and a double-blind, placebo-controlled 
randomized phase. The open-label safety run-in phase of 25 patients es-
tablished that combined use of vandetanib 300 mg with CP was gener-
ally well tolerated. The primary objective of the randomized phase was 
to determine whether vandetanib (300 mg/day) ± CP (C, target AUC
ss
 
= 6 mg/ml•min; P, 200 mg/m2 i.v.) prolonged progression-free survival 
(PFS) vs CP alone. The study was designed to have a >75% power 
to detect a 30% prolongation at a 1-sided signiﬁcance level of P<0.2. 
Secondary objectives included assessments of objective response rate, 
overall survival, safety and tolerability.
Results: In the randomized phase, 181 patients (median age 61 yrs, 
range 27–83) received vandetanib (n=73), vandetanib + CP (n=56) or 
CP alone (n=52). The vandetanib monotherapy arm was stopped early 
after a planned interim PFS analysis met the criterion for discontinu-
ation (HR > 1.33 vs CP); eight patients continued to receive mono-
therapy for >6 months (190–529 days). Nonetheless, the primary 
objective was met, with vandetanib + CP prolonging PFS vs CP (hazard 
ratio [HR] = 0.76, 2-sided 95% CI, 0.50–1.15; P=0.098 [1-sided], 
0.197 [2-sided]). Median PFS was 24 weeks (vandetanib + CP) and 
23 weeks (CP). The objective response rates were 32% (vandetanib 
+ CP), 25% (CP) and 7% (vandetanib). Overall survival (OS) was 
not signiﬁcantly different between patients receiving vandetanib + 
CP and CP (HR = 1.07, 95% CI, 0.63–1.81; P=0.595 [1-sided], 0.811 
[2-sided]). Exploratory subgroup analyses suggest advantages in PFS 
and OS for vandetanib + CP vs CP in the female and non-smoking 
patient subgroups, although the numbers in these subgroups were small 
(n=32 and 24, respectively). The adverse event proﬁle was consistent 
with that observed in other vandetanib studies in NSCLC. There was 
a higher incidence of some adverse events with vandetanib + CP vs 
CP, including rash (64% vs 33%), diarrhea (53% vs 32%), asymptom-
atic QTc-related events (22% vs 4%) and hypertension (32% vs 4%). 
Patients receiving vandetanib + CP, including seven who entered with 
CNS metastases and 11 with squamous histology, did not experience 
any intracranial bleeding, or hemoptysis of CTC grade 2 or higher. A 
biomarker analysis of the relationship between circulating endothelial 
cell levels and clinical outcome will be reported separately. 
